How should a patient be switched from the rivastigmine transdermal patch to oral rivastigmine, including equivalent dosing and titration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Rivastigmine Patch to Oral Formulation

When switching from rivastigmine transdermal patch to oral capsules, use the following dose conversions: patients on the 4.6 mg/24 hours patch should switch to less than 6 mg/day oral (typically 3 mg/day), and patients on the 9.5 mg/24 hours patch should switch to 6-12 mg/day oral (typically starting at 6 mg/day). Apply the first oral dose on the day following removal of the last patch 1.

Dose Conversion Algorithm

The FDA-approved rivastigmine label provides clear guidance for the reverse conversion (oral to patch), which can be applied in reverse for patch-to-oral switches 1:

For patients on 4.6 mg/24 hours patch:

  • Switch to oral rivastigmine starting at 1.5 mg twice daily (3 mg/day total)
  • This represents the initial oral dosing regimen
  • Remove the final patch and begin oral dosing the following day

For patients on 9.5 mg/24 hours patch:

  • Switch to oral rivastigmine 3 mg twice daily (6 mg/day total) initially
  • Can titrate up to 6 mg twice daily (12 mg/day total) as tolerated
  • Remove the final patch and begin oral dosing the following day

For patients on 13.3 mg/24 hours patch:

  • Switch to oral rivastigmine 6 mg twice daily (12 mg/day total)
  • This represents the maximum oral dose
  • Remove the final patch and begin oral dosing the following day

Titration Considerations

After the initial switch, titrate oral doses slowly—increase by 1.5 mg twice daily (3 mg/day total) no more frequently than every 4 weeks 2. This gradual titration minimizes gastrointestinal side effects (nausea, vomiting, diarrhea), which occur significantly more frequently with oral formulations compared to patches 3, 4.

Critical caveat: Oral rivastigmine has substantially higher peak plasma concentrations (Cmax 21.6 ng/ml) compared to the patch (8.7 ng/ml), despite similar overall drug exposure 4. This results in 3-fold higher rates of nausea (23% vs 7%) and vomiting (17% vs 6%) with oral formulations 3, 4. Taking oral rivastigmine with food reduces these gastrointestinal effects 2.

Monitoring After Conversion

Monitor closely for:

  • Gastrointestinal symptoms (nausea, vomiting, diarrhea)—most common with oral formulation
  • Weight loss—specific concern with rivastigmine 2
  • Cognitive and functional status—assess at 6-12 months to ensure maintained therapeutic benefit 2
  • Adherence—twice-daily oral dosing may be more challenging than once-daily patch application

Common Pitfalls to Avoid

Do not abruptly discontinue the patch without starting oral therapy. If treatment is interrupted for more than 3 days, restart at the lowest dose (1.5 mg twice daily) and retitrate 1.

Do not assume dose equivalence is exact. The patch provides more consistent drug delivery over 24 hours with less fluctuation, while oral formulations have higher peaks and troughs 4. Some patients may require dose adjustments after switching.

Do not overlook the reason for switching. If the switch is due to skin reactions from the patch, this is appropriate. However, if switching for convenience, recognize that the patch formulation has superior tolerability with similar efficacy 3, 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.